BioCentury
ARTICLE | Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

October 26, 2018 4:36 PM UTC

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported that its other nicotinic acetylcholine receptor (nAchR) agonist nasal spray, OC-02, missed the same endpoint in the Phase IIb RAINIER trial in the indication.

OC-01 and OC-02 are both potential first-in-class, ocular-surface sparing treatments designed to stimulate the trigeminal nerve, accessible within the nose, to promote natural tear film production. According to the company, the products have slightly different binding profiles...